# EDGAR Filing Document

**Accession Number:** 0001434265
**File Stem:** 0001193125-25-326263
**Filing Date:** 2025-12
**Character Count:** 13097
**Document Hash:** c848a78d9f2c060c6fe7570297794944
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-326263.hdr.sgml**: 20251219

**ACCESSION NUMBER**: 0001193125-25-326263

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20251219

**DATE AS OF CHANGE**: 20251219

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Merus N.V.
- **CENTRAL INDEX KEY:** 0001651311
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-89510
- **FILM NUMBER:** 251586509

**BUSINESS ADDRESS:**
- **STREET 1:** YALELAAN 62
- **CITY:** 3584 CM UTRECHT
- **STATE:** DE
- **BUSINESS PHONE:** 31 030 253 8800

**MAIL ADDRESS:**
- **STREET 1:** YALELAAN 62
- **CITY:** 3584 CM UTRECHT
- **STATE:** DE

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Merus B.V.
- **DATE OF NAME CHANGE:** 20150819
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GENMAB A/S
- **CENTRAL INDEX KEY:** 0001434265
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** TOLDBODGADE 33
- **CITY:** 1253 COPENHAGEN K
- **STATE:** G7
- **ZIP:** 00000

**MAIL ADDRESS:**
- **STREET 1:** TOLDBODGADE 33
- **CITY:** 1253 COPENHAGEN K
- **STATE:** G7
- **ZIP:** 00000

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex99_a.pdf`

_No text found in this document._

**Attachment 2:** `ck0000000000-ex99_f.pdf`

_No text found in this document._

**Attachment 3:** `ck0000000000-ex99_g.pdf`

_No text found in this document._

**Attachment 4:** `ck0000000000-ex99_h.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Merus N.V.**

*(Name of Issuer)*

**Common Shares, Euro 0.09 nominal value per share**

*(Title of Class of Securities)*

**N5749R100**

*(CUSIP Number)*

**Greg Mueller**<br>Carl Jacobsens Vej 30<br>Valby G7 2500<br>45 70 20 27 28

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/12/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **N5749R100** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Genmab A/S** | Name of reporting person<br>**Genmab A/S** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**G7** | Citizenship or place of organization<br>**G7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**71946801.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**71946801.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**71946801.00** | Aggregate amount beneficially owned by each reporting person<br>**71946801.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**94.8%** | Percent of class represented by amount in Row (11)<br>**94.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **N5749R100** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Genmab Holding II B.V.** | Name of reporting person<br>**Genmab Holding II B.V.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**P7** | Citizenship or place of organization<br>**P7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**71946801.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**71946801.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**71946801.00** | Aggregate amount beneficially owned by each reporting person<br>**71946801.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**94.8%** | Percent of class represented by amount in Row (11)<br>**94.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares, Euro 0.09 nominal value per share

**(b) Name of Issuer:**
Merus N.V.

**(c) Address of Issuer's Principal Executive Offices:**
Uppsalalaan 17, Utrecht, P7, 3584 CT

This statement on Schedule 13D (this "Schedule 13D") relates to the tender offer by Genmab Holding II B.V. ("Purchaser"), a wholly owned subsidiary of Genmab A/S ("Parent"), for all of the issued and outstanding common shares, Euro 0.09 nominal value per share (the "Common Shares"), of Merus N.V., a public limited liability company (naamloze vennootschap) organized under the Laws of The Netherlands (the "Issuer"), at a price of $97.00 per Common Share, in cash, without interest and subject to any applicable withholding taxes (the "Offer"), upon the terms and subject to the conditions set forth in the Schedule TO filed with the United States Securities and Exchange Commission (the "SEC") on October 21, 2025 (together with any amendments and supplements thereto, the "Schedule TO"), a copy of which is attached as Exhibit B to this Schedule 13D, and in the offer to purchase dated October 21, 2025 (together with any amendments and supplements thereto, the "Offer to Purchase"), a copy of which is attached as Exhibit C to this Schedule 13D, and the related letter of transmittal (the "Letter of Transmittal"), a copy of which is attached as Exhibit D to this Schedule 13D. This Schedule 13D also relates to the Transaction Agreement, dated as of September 29, 2025 (the "Transaction Agreement"), by and between Parent, Purchaser and the Issuer, a copy of which is attached as Exhibit E to this Schedule 13D, pursuant to which the Offer was made.

**Item 4. Purpose of Transaction**

The purpose of the transactions described in this Schedule 13D is for the Reporting Persons to acquire control of all of the issued and outstanding Common Shares of the Issuer while allowing all of the Issuer's shareholders an opportunity to receive the purchase price of $97.00 per Common Share by tendering their Common Shares pursuant to the Offer.

Promptly following the expiration of the subsequent offering period of the Offer, the listing of the Common Shares on The Nasdaq Stock Market LLC will be terminated, and the Common Shares will be deregistered under the Act, resulting in the cessation of the Issuer's reporting obligations to the SEC with respect to the Common Shares.
The information set forth in the section of the Offer to Purchase entitled "Summary Term Sheet" and "Purpose of the Offer; Back-End Transactions; Plans for Merus" is incorporated herein by reference.

The foregoing summary is qualified in its entirety by the full text of the Offer to Purchase, which are filed as exhibits to this Schedule 13D and incorporated herein by reference. The information set forth under Item 5 of this Schedule 13D is incorporated herein by references.

**Item 5. Interest in Securities of the Issuer**

**(a)**
(a) and (b), the Reporting Persons may be deemed to beneficially own, in the aggregate, 71,946,801 Common Shares, representing approximately 94.8% of the Issuer's outstanding Common Shares (based upon the 75,865,294 Common Shares stated to be outstanding as of December 12, 2025 by Equiniti Trust Company, LLC, in its capacity as depositary for the Common Shares).

Purchaser has voting power and dispositive power with regard to 71,946,801 Common Shares. Parent, by virtue of its relationship to Purchaser (as disclosed in Item 2), may be deemed to indirectly beneficially own (as such term is defined in Rule 13d-3 under the Act) the Common Shares which Purchaser directly beneficially owns.

On December 12, 2025, following the expiration of the initial offering period of the Offer at 5:00 p.m., New York City time on December 11, 2025, Purchaser accepted for payment, and thus acquired, 71,463,077 Common Shares tendered pursuant to the Offer at a purchase price of $97.00 per Common Share in cash, without interest and less applicable withholding taxes.  In addition, on December 12, 2025, Purchaser commenced a subsequent offering period, which is scheduled to expire at 5:00 p.m., New York City time on December 29, 2025.

From December 12, 2025 to December 18, 2025, Purchaser acquired 483,724 Common Shares tendered during subsequent offering period at a purchase price of $97.00 per Common Share in cash, without interest and less applicable withholding taxes.

**(b)**
The information in Item 5(a) is incorporated herein by reference.

**(c)**
Except as described above or in the remainder of this paragraph, there were no other transactions with respect to Common Shares effected during the past 60 days by the Reporting Persons, or to the knowledge of the Reporting Persons, any of the persons listed in Schedule I of the Offer to Purchase

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth under Items 3, 4 and 5 of this Schedule 13D and the information set forth in the section of the Offer to Purchase entitled "Purpose of the Offer; Back-End Transactions; Plans for Merus" and "The Transaction Agreements" is incorporated herein by reference.

The foregoing summary is qualified in its entirety by the full text of the Offer to Purchase, the Letter of Transmittal, the Transaction Agreement, which are filed as exhibits to this Schedule 13D and incorporated herein by reference.

Except as set forth in this Schedule 13D, none of the Reporting Persons or any of the persons listed in Schedule I of the Offer to Purchase have any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including, but not limited to, any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Genmab A/S

**Signature:** /s/ Jan G. J. van de Winkel

**Name/Title:** Jan G. J. van de Winkel, President & Chief Executive Officer

**Date:** 12/19/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Genmab Holding II B.V.

**Signature:** /s/ Jan G. J. van de Winkel

**Name/Title:** Jan G. J. van de Winkel, Authorized Signatory

**Date:** 12/19/2025